

2026/10/20

RIBOMIC Enters into Technology Evaluation Agreement for DDS Aptamer Asset with a Foreign Biotech Company

TOKYO, October 20, 2026 — RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, announced that following approval by its President and CEO, the company has entered into a technology evaluation agreement with a biotechnology company based outside Japan to evaluate RIBOMIC's proprietary Drug Delivery System (DDS) aptamer technology.

1. Background and Purpose of the Agreement

RIBOMIC has been advancing DDS aptamer technologies by leveraging the distinctive characteristics of aptamers, including their high affinity for target molecules and ease of chemical modification. RIBOMIC aims to enable targeted drug delivery by conjugating tissue-targeting aptamers with a variety of therapeutic modalities. In addition, RIBOMIC is developing technologies for the efficient delivery of nucleic acid therapeutics, addressing one of the key challenges in the field, with the potential for broad application across therapeutic areas with substantial unmet medical needs.

Under the agreement, RIBOMIC will provide its DDS aptamer to the partner company for the purpose of a technology evaluation. In consideration of the evaluation, RIBOMIC expects to receive a fee of US\$53,000 from the partner company. This agreement is a technology evaluation agreement relating to a specific R&D theme and does not guarantee the establishment of a business alliance or collaborative research arrangement.

The name of the partner company and other details have not been disclosed in accordance with the confidentiality obligations agreed between the parties.

This agreement represents the sixth technology evaluation agreement under RIBOMIC's drug discovery support business. RIBOMIC considers this agreement an important step toward advancing future R&D activities and creating new business opportunities. Other than the agreement announced herein, there are no capital ties, personnel relationships, business

relationships, or related-party relationships between the partner company and RIBOMIC.

2. Future Outlook

The evaluation fee is expected to be recognized as revenue in the fiscal year ending March 31, 2027. Taking into account the impact of this agreement, RIBOMIC has separately announced today a revision to its earnings forecast for the fiscal year ending March 31, 2027.

Please visit the RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information: RIBOMIC Inc.

ir.inquiry@ribomic.com